Not yet recruitingInterventionalPhase 2Last updated Aug 10, 2026

Off-Label Treatment With Immune Checkpoint Inhibitor Blockade

Overview

ClinicalTrials.gov ID: NCT07754292
Lead Sponsor: Medical College of WisconsinOTHER
Brief Summary: This is a phase II therapeutic interventional clinical trial that will evaluate the efficacy, safety, and outcomes of off-label immune checkpoint blockade use across malignancies.
Study Type: Interventional

Interventions

Drug: One or more off-label ICIs alone or with other on-label ICI(s)Drug: Off-label ICI(s) with targeted therapyDrug: off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents

Status

Overall Status: Not yet recruiting
Start Date: Nov 1, 2026Estimated
Primary Completion Date: Nov 1, 2032Estimated
Completion Date: Nov 1, 2036Estimated

Study Record Dates

First Submitted: Aug 4, 2026
First Submitted that Met QC Criteria: Aug 4, 2026
First Posted: Aug 10, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 4, 2026
Last Update Posted: Aug 10, 2026Actual
Last Verified: Aug 2026

NCT03514368Recruiting

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

NCT04629339Terminated

Study of INCB086550 in Select Solid Tumors

NCT04580485Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

NCT05429866Unknown status

Immunological Variables Associated to ICI Toxicity in Cancer Patients

NCT06388031Recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

NCT05572684Terminated

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors